David Lamond - 24 May 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role
Director
Signature
/s/ David Lamond
Issuer symbol
QNCX
Transactions as of
24 May 2023
Net transactions value
$0
Form type
4
Filing time
26 May 2023, 17:47:13 UTC
Previous filing
09 Jun 2022
Next filing
17 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Stock Option (right to buy) Award $0 +27,000 $0.000000 27,000 24 May 2023 Common Stock 27,000 $1.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023.